Founded by scientist Rahul Mehta, dermatologist Doris Day, and executive Brent Saunders, the company differentiates itself by moving beyond topical treatments that mask cosmetic aging. Instead, the team focuses on the TORC1 cellular pathway, a fundamental mechanism linked to age-related decline. The company’s flagship product, the Pro-Longevity Face Serum, utilizes the proprietary molecule RLX-201, which originated from the TORnado platform developed by Cambrian Bio.
Dr. Mehta stated that the funding allows the firm to integrate its longevity-focused solutions into dermatology practices nationwide. The company is simultaneously expanding its leadership, appointing Neetu Dhaliwal and Dr. Craig Gordon to its Board of Directors. Beyond skincare, the new capital supports research into hair health and additional dermatological applications, aiming to establish a specialized category that treats skin health as a long-term biological process rather than a surface-level concern.
Comments (0)
No comments yet. Be the first!